News

ArriVent Press Releases

Ivesa® Demonstrates Progression Free Survival of Over 20 Months in First-Line Setting for EGFR-Mutated Advanced NSCLC

Results from FURLONG study published by The European Lung Cancer Congress Shanghai, China – March…

<img alt='Josh Comolli' data-srcset='https://secure.gravatar.com/avatar/e0172373a5125e8449a50d7ae0ebd880?s=140&d=mm&r=g 2x' height='70' width='70' data-src='https://secure.gravatar.com/avatar/e0172373a5125e8449a50d7ae0ebd880?s=70&d=mm&r=g' class='avatar avatar-70 photo lazyload' src='data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==' /><noscript><img alt='Josh Comolli' src='https://secure.gravatar.com/avatar/e0172373a5125e8449a50d7ae0ebd880?s=70&d=mm&r=g' srcset='https://secure.gravatar.com/avatar/e0172373a5125e8449a50d7ae0ebd880?s=140&d=mm&r=g 2x' class='avatar avatar-70 photo' height='70' width='70' />

Josh ComolliMarch 31, 2022

ArriVent Press Releases

ArriVent Biopharma Appoints Bahija Jallal to its Board of Directors

ArriVent Biopharma Appoints Bahija Jallal to its Board of Directors NEWTOWN SQUARE, PA—February 15, 2022—ArriVent…

<img alt='Josh Comolli' data-srcset='https://secure.gravatar.com/avatar/e0172373a5125e8449a50d7ae0ebd880?s=140&d=mm&r=g 2x' height='70' width='70' data-src='https://secure.gravatar.com/avatar/e0172373a5125e8449a50d7ae0ebd880?s=70&d=mm&r=g' class='avatar avatar-70 photo lazyload' src='data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==' /><noscript><img alt='Josh Comolli' src='https://secure.gravatar.com/avatar/e0172373a5125e8449a50d7ae0ebd880?s=70&d=mm&r=g' srcset='https://secure.gravatar.com/avatar/e0172373a5125e8449a50d7ae0ebd880?s=140&d=mm&r=g 2x' class='avatar avatar-70 photo' height='70' width='70' />

Josh ComolliFebruary 15, 2022

ArriVent Press Releases

Aarvik Therapeutics and ArriVent Biopharma Announce Research Collaboration to Advance Novel Oncology Drug Candidate Using Aarvik’s Proprietary Modular Antibody Platform

Aarvik Therapeutics and ArriVent Biopharma Inc. announce a strategic research collaboration to develop and commercialize…

<img alt='Josh Comolli' data-srcset='https://secure.gravatar.com/avatar/e0172373a5125e8449a50d7ae0ebd880?s=140&d=mm&r=g 2x' height='70' width='70' data-src='https://secure.gravatar.com/avatar/e0172373a5125e8449a50d7ae0ebd880?s=70&d=mm&r=g' class='avatar avatar-70 photo lazyload' src='data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==' /><noscript><img alt='Josh Comolli' src='https://secure.gravatar.com/avatar/e0172373a5125e8449a50d7ae0ebd880?s=70&d=mm&r=g' srcset='https://secure.gravatar.com/avatar/e0172373a5125e8449a50d7ae0ebd880?s=140&d=mm&r=g 2x' class='avatar avatar-70 photo' height='70' width='70' />

Josh ComolliDecember 23, 2021

ArriVent Press Releases

ArriVent Biopharma Launches with Up To $150M in Series A Financing and Strategic Licensing Agreement for Clinical-Stage Oncology Asset

Funds will be used to build ArriVent’s portfolio of innovative in-licensed assets for global development…

Amy HirschJune 30, 2021